This session explores emerging mechanisms that govern the development and progression of metabolic dysfunction–associated steatotic liver disease and steatohepatitis. Presentations will examine how hepatocyte metabolic programs, macrophage efferocytosis, bile acid signaling, natural killer cell dysfunction, aging-related ferroptosis, and fibrosis-associated cellular states contribute to liver injury and fibrogenesis. The session will also highlight translational insights from preclinical models, including the potential of FGF21-based therapy to promote fibrosis regression and prevent hepatocellular carcinoma.

This session will highlight emerging approaches to identifying patients with steatotic liver disease who are at greatest risk for advanced liver disease and adverse outcomes. Presentations will explore the role of lipid biomarkers, body phenotype, alcohol exposure assessment, noninvasive diagnostic criteria, and adaptive machine-learning strategies. Together, these studies underscore the evolving role of precision risk stratification in MASLD, MASH cirrhosis, and clinical trial prescreening.

This session focuses on emerging mechanisms of liver fibrogenesis and novel antifibrotic therapeutic strategies. Topics include hepatic stellate cell activation, extracellular matrix remodeling, metabolic and epigenetic regulation of fibrosis, and innovative cell- and RNA-based therapies. Through mechanistic and translational studies, speakers will highlight new opportunities to prevent, halt, and reverse liver fibrosis.
 

This session presents current research on health disparities and health equity in chronic liver diseases in the United States. Topics include disparities in treatment access, rural versus urban outcomes, the role of social determinants of health in surveillance and therapy, patient portal engagement, and shifting drivers of liver cancer.

This session presents current research on health equity and disparities in liver transplantation and advanced liver disease in the United States. There is a significant focus on variable access to lifesaving treatments for end stage liver disease, with variability based on geographic, insurance-based, and racial or ethnic factors. 

Presidential Basic Science Plenary Abstracts that highlight advances and  discoveries for liver biology and pathobiology rooted in pre-clinical and translational research.

The recent increase in the global utilization of normothermic machine perfusion is changing day-to-day practice of liver transplantation, with new logistics and complexities.

Alcohol is a major contributor to liver disease, yet diagnostic plans and treatment approaches are not standard around the globe.  This SOA lecture is aimed to explore a multidisciplinary appraoch to evaluation and treatment.

Very recent experiences of gene therapy for non-liver disorders has, in rare cases, led to several serious hepatic toxicities including liver failure.  Understanding hepatic pathophysiology, monitoring and therapeutic approaches in the modern era of gene therapy is crucial.

This session features industry-sponsored preclinical and translational research spanning novel therapeutics for Alagille syndrome, PSC, alcohol use disorder, and decompensated cirrhosis, plus hepatocyte engineering advances.